Our leaders are passionate, empowered and committed to our mission to make a difference in the lives of patients.
A real Jeff of all trades, you'll find this adventurous CEO catching waves on his 9-foot Mega Magic longboard...that is, when he's not busy roasting his own coffee beans.
Jeff joined Sage as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the Sage team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals (now known as Ionis Pharmaceuticals), as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.
Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.
When he's not cooking meals for his family and friends, Steve enjoys serving as head coach of the all-girl robotics team, the "Radical Robots," in Swarthmore, PA.
Steve joined Sage as CMO in 2013. Steve is a former practicing psychiatrist and previously served as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division of AstraZeneca Pharmaceuticals. At AstraZeneca, he also served as the Chair of the Neuroscience Safety Knowledge Group. During his time at AstraZeneca, Steve served as the Medical Science Senior Director for the neuroscience established brands and emerging anesthesia group product team and in other positions of increasing responsibility in the neuroscience discovery medicine, early and late development groups. Prior to joining AstraZeneca, he was a faculty member in the psychiatry department at the University of Pennsylvania School of Medicine, where he continues to serve as an adjunct assistant professor of psychiatry. Steve has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry.
Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.
When Al’s not discovering new medicines, he is spending his time in the water, under the water or on the water. He loves diving, white water rafting, wake boarding – anything that gets him into a body of water!
Al joined Sage as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. Prior to Lundbeck, Al was Senior Director and Head of the Neuroscience Discovery Chemistry Department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. Al has co-authored more than 125 manuscripts and abstracts, and is a co-inventor on 50 patents and patent applications.
Al holds a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.
A chemist turned CFO, Kimi feels as comfortable crunching numbers as she does creating compounds. Perhaps she's most in her element when she trades ions for irons out on the golf course, where you'll find her in her free time.
Kimi joined Sage as CFO in 2013, bringing both financial and operating strength from her senior management experience at Millennium, Biogen and emerging life science companies. Prior to joining Sage, Kimi served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals. Prior to that, she held the role of Vice President of Finance at Cyberkinetics Neurotechnology Systems. Previously, Kimi was the Senior Director of Financial Reporting and Analysis at Millennium Pharmaceuticals and the Senior Manager of External Reporting at Biogen, Inc. She also worked as a business assurance manager at PricewaterhouseCoopers LLP and started her career in chemistry-related positions at various Boston-based companies.
Kimi holds a B.A. in chemistry from Drew University and an M.B.A. from Northeastern University. She earned her CPA in Massachusetts.
Mike coaches youth sports. He enjoys spending his free time on the court or in the field, and particularly likes spending time with his wife and four children. As a family, they love to travel, play sports and create new family traditions.
Mike joined Sage as Chief Business Officer in April 2017 and leads the Commercial, Portfolio and Program Management, Medical Affairs, and Corporate Development departments. Previously, he served as Senior Vice President, US Commercial, at Biogen where he led the US affiliate with direct general manager responsibility for Sales, Marketing, Market Access, Patient Services and Commercial Operations. During Mike’s 14-year tenure at Biogen, he held roles of increasing responsibility, including Senior Vice President, Global Commercial Strategy; Vice President, Managing Director, Australia/New Zealand affiliate; and Vice President, Business Planning. Prior to Biogen, he worked at Bain & Company as a consultant specializing in healthcare. Mike earned his M.B.A. from Darden Graduate School of Business Administration, University of Virginia and a B.A. from College of the Holy Cross.
Jim is an avid sports fan, and when he's not at SAGE, you'll find him playing golf, softball, Ultimate Frisbee or tennis (though lately, he admits he's more likely to be watching said sports on TV).
Jim joined Sage in 2012 with more than 14 years of experience in neuroscience drug discovery and development. He most recently served as Director and Head of Neuroscience for the CNS and pain innovative medicine unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden, where he was responsible for leading preclinical research in neurology and pain control. Prior to that, he was Director and Head of the Neuroscience Department at AstraZeneca Pharmaceuticals in Wilmington, Del., where he was responsible for leading preclinical research in psychiatry and cognition. He has experience with discovery, translational science and early development in several areas of neuroscience research, including psychiatry, neurology, cognition, epilepsy and analgesia. Jim has led multiple teams to deliver candidate compounds into clinical development. He has authored more than 30 peer-reviewed research and review articles.
Jim holds a B.A. in biology from the University of Delaware and a Ph.D. in neuroscience from Georgetown University. He was a post-doctoral fellow at Emory University Medical School.
From engineering offshore pipelines and platforms in the North Sea and Gulf of Mexico, to running his boat or grooving trails on the ski slopes, one thing is clear: Tom the builder loves to build (and a good adventure)!
Tom joined Sage in April 2014 as Chief Commercial Strategy Officer. Prior to Sage, Tom served as Senior Vice President, Corporate Strategy and Commercial Assessment at Shire plc and served as General Manager for several of Shire’s psychiatry and neurology products. In addition, he led Shire’s specialty pharmaceutical commercial operations, business information and strategic marketing functions, and played a lead role in business development efforts. Prior to Shire and in two separate tenures, he spent 17 years in Johnson & Johnson’s pharmaceutical companies, notably Janssen and Ortho-McNeil, where he held senior-level roles in marketing, marketing research, sales and sales management, operations and engineering. In between employments at Johnson & Johnson, he was President and Chief Executive Officer of Ranir Corporation – a dental products company – where he was also a Corporate Officer and Director, and Executive Vice President and Chief Operating Officer of Lander Co., Inc., a healthcare-related consumer packaged goods company, where he was previously a Corporate Officer.
Tom holds a B.S. in civil engineering from Lehigh University and an M.B.A. in finance from the University of Notre Dame.
In her free time, Anne Marie enjoys horseback riding and spending time with family.
Anne Marie Cook joined Sage as General Counsel in 2015. Before joining Sage, Anne Marie served as Senior Vice President, General Counsel and Secretary at Aegerion Pharmaceuticals. Before that, she was a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate), where she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property. Additionally, she provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, she was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc., and Chief Corporate Counsel at Biogen.
Anne Marie holds a B.S. in biology from Tufts University and a J.D. from the University of Notre Dame Law School.
In his free time, Heinrich’s main focus is spending time with family and friends. He likes to travel and explore new activities. In order to keep up with his daughter, he started to skateboard (so far without major injuries). He also enjoys scuba-diving and sailing.
Heinrich joined Sage in 2015 as Senior Vice President, Technical Operations. Before joining Sage, he served as Vice President, Process Development & Manufacturing at Cubist, Inc., where he was responsible for developing manufacturing processes for new products, all CMC related development and for overseeing external manufacturing partners for clinical stage and commercial products. Prior to his 10-year tenure at Cubist, he held various positions in process development and manufacturing support at Hoffman-La Roche in Switzerland, New Jersey and Germany.
Heinrich holds both a chemistry degree and a Ph.D. in biochemical engineering from the Braunschweig University of Technology, Germany.
In her free time, Erin enjoys spending time with friends and family, traveling, and exploring new places. She spends many hours enjoying the variety of activities of her two daughters.
Erin joined Sage in 2014 bringing more than 20 years of experience in developing human resources strategies and programs to the company. Before joining the Sage team, Erin served as Executive Director, Human Resources, Global Commercialization at Bristol-Myers Squibb (BMS), joining the company through its October 2007 acquisition of Adnexus, where she was the Vice President, Human Resources and a member of the executive leadership team responsible for driving strategy and ensuring a successful integration of Adnexus into BMS. In 2009, Erin relocated to Paris where she was the HR Director for European Markets at BMS, serving as the strategic business partner responsible for all aspects of HR across multiple European commercial, R&D and corporate functions.
Prior to BMS, Erin was Vice President of Human Resources at Therion Biologics Corporation, where she was instrumental in defining and creating the company's culture and HR infrastructure. Prior to Therion, she served as the Director of Human Resources for ViaCell and as a Human Resources Business Partner at Genzyme Corporation for the therapeutics and international divisions and was a Founder/Partner of Outsourcing Solutions, Inc., a human resources consulting firm.
Erin earned her B.S. in Business Administration from Northeastern University.
Amy spends most of her spare time with family and friends, including her husband, two daughters and a rescued Golden Doodle named Sandy. Her hidden talents include playing piano, gardening and sewing (a lost art!).
Amy brings to Sage extensive expertise in regulatory affairs and quality assurance, with more than 20 years of experience in the biotech and life science industries, including more than 15 years in executive management. She most recently served as Vice President, Regulatory Affairs at Sunovion Pharmaceuticals (previously Sepracor), where she worked for 10 years, also serving as Executive Director and Senior Director of Regulatory Affairs. At Sunovion, she led regulatory strategy regarding clinical development of CNS compounds and later managed development and commercial regulatory activities for all drug, biologic and combination device products at the company's Marlborough campus. Prior to Sunovion, Amy spent seven years leading the regulatory affairs function at Stryker Biotech, where she determined successful regulatory strategies for biologic orthopaedic products and was an integral part of the quality team.
Amy received her B.S. in biomedical engineering at Rensselaer Polytechnic Institute and her Ph.D. and M.S. in biomedical engineering at the University of Virginia. She was recently named as one of the Boston Business Journal/Mass High Tech 2014 Women to Watch.
Kevin is a proven operational leader with more than 25 years of experience building and operating leading biotech companies. Kevin co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of the firm's portfolio companies as well as actively identifying and evaluating new investments. Prior to Third Rock Ventures, Kevin was Chief Operating Officer and Chief Financial Officer at Millennium Pharmaceuticals, where he led key roles in raising billions of dollars in capital through strategic alliances and public financing and driving growth through company expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen and Digital Equipment Corporation. He is currently a Board Member of Alnylam Pharmaceuticals.
Kevin holds a M.S. in Corporate Finance from Boston College and a B.A. in Mathematics and Business from Colby College.
Jeff joined SAGE as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.
Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.
Steve has had a distinguished 40-year career in neuroscience, particularly in molecular neuropharmacology and CNS drug discovery and development. Steve is the scientific co-founder of Sage Therapeutics and served as its interim start-up Head of R&D. He is also the co-founder of Voyager Therapeutics, a CNS gene therapy company, and currently serves as its President and CEO. Steve is the former Director of the Appel Alzheimer Disease Research Institute at Weill Cornell Medical College and is currently an Adjunct Professor of Psychiatry at Washington University of St. Louis School of Medicine. Prior to his appointments at Weill Cornell and Washington University, Steve spent 17-years at Eli Lilly and Company, during which time he held several key leadership roles, including Vice President of Neuroscience and Clinical Investigation, Executive Vice President for Science and Technology, and President of the Lilly Research Laboratories, where he was responsible for the company's overall research and development efforts. Prior to Lilly, Steve spent 18 years at NIH as a Laboratory / Branch Chief and as the Scientific Director of the National Institute of Mental Health.
Steve has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored more than 550 papers and book chapters. Steve is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine of the National Academy of Sciences. He is also an elected Fellow Emeritus of the American College of Neuropsychopharmacology (ACNP) and served as ACNP President (1999). Steve is also currently on the board of directors or is a trustee of several organizations, including serving as Chairman of the Board of the Foundation for the NIH (FNIH) and as a Director of Alnylam Pharmaceuticals and Voyager Therapeutics. Steve has also served as a member of the National Institute of General Medical Sciences (NIGMS) and the National Institute of Mental Health Advisory Councils and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the Advisory Committee to the Director of the NIH from 2001-2006 as well as to the Science Board of the FDA (2012-2014).
Steve received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.
Jim serves as Senior Vice President and Chief Financial Officer of Alkermes. Prior to joining Alkermes in 1998, Jim was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Jim served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. He also serves as a Trustee and Treasurer of St. Paul's School. Jim received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.
Michael currently serves as president and chief executive officer of Medgenics, Inc. Prior to joining Medgenics, he served as president of specialty pharmaceuticals at Shire plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management. Previously, Michael also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc. In addition, Michael has held senior positions in product development and commercialization at AstraMerck and AstraZeneca.
Michael received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He also serves on the board of directors at Vanda Pharmaceuticals Inc. and Pennsylvania BIO, and serves as chairman for the board of governors of the Boys & Girls Clubs of Philadelphia.
Geno was most recently President of Intrexon, a leader in synthetic biology, from June 1, 2016 to March 2017. As President, Mr. Germano led Intrexon's management team and commercialization efforts utilizing the Company's technology platform for biologically-based solutions across a broad range of industries including Health, Consumer, Energy, Environment and Food.
Mr. Germano has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value. He held numerous leadership roles in multiple therapeutic categories and global markets at Pfizer, Wyeth and Johnson & Johnson. Prior to joining Intrexon, he was Group President of Pfizer's Global Innovative Pharma Business, where he consistently grew this $14 billion global business and guided the development of an extensive portfolio of late-stage development candidates in the cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases therapeutic areas. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee focused on maximizing the return on research and development investment across the Pfizer portfolio. Previously, Mr. Germano served as President and General Manager of Pfizer's Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets, as well as held responsibility for driving P&L growth and pipeline value through disciplined portfolio management. In addition, while in this role he directed the integration of Wyeth and Pfizer Specialty Care and Vaccines Businesses and developed top talent within the organization focusing on the leadership team.
Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., where he was responsible for delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women's Healthcare Business. He has been a member of the Group of Fifty (G50) and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee and Chaired the International Committee. He continues to serve on the Advisory Board of the Healthcare Businesswomen's Association and as a Trustee of the Albany College of Pharmacy where he received his Bachelor of Science degree in Pharmacy. Geno was formerly a Director of Zoetis Inc., and is currently a director of Bioverativ.
Asha most recently served as chief medical officer at Intel Corporation where she guided its healthcare investment strategy and provided clinical and business leadership to Intel’s broad spectrum of healthcare programs. She served as co-principal investigator on four clinical studies that demonstrated the value of Intel technologies in the areas of oncology and preventative cardiology. Asha’s work played a seminal role in the development of brain MRI for stroke diagnosis in addition to multiple interventional cardiology tools in use today. Before joining Intel, she was vice president at New Leaf Venture Partners, guiding its investments in the medical device sector. Earlier, Asha created and led several new therapy programs at Medtronic. Now, and throughout her career, she maintains an active clinical practice at the Stanford VA emergency department. She is the inventor on numerous patents and is published in several textbooks and peer-reviewed journals.
Asha holds an M.D. and Ph.D. in neuroscience from the University of Colorado and completed internal medicine residency and Biodesign Innovation Fellowship programs at Stanford University.